Vision growth pauses while surgical business stays in house
- Vision sales were flat in the recent quarter due to a planned inventory reduction in the U.S. market.
- The board decided against selling the surgical business after a strategic review.
- A new rival product threatens Paragard in the non-hormonal IUD market.
- Heavy investment in the vision sales force could pressure profit margins early next year.
A paused sale and a vision reset
The picture shifted this quarter after management decided to keep CooperSurgical. The board had run a strategic review but found that a recent litigation settlement and a new competitor in the IUD market hurt the valuation too much to sell.
At the same time, the main growth engine stalled. CooperVision revenue was flat at $717 million in the third quarter. Management said this was caused by a planned inventory reduction in the U.S. that will continue into the fourth quarter, even though actual patient demand remains healthy.
The bull case focuses on cash generation and a cleaner setup for 2027. Keeping CooperSurgical leaves a business that generated record free cash flow in the third quarter. If the vision inventory issues end as promised, CooperVision could return to strong growth next year as its expanded sales force gets to work.
The bear case highlights new competitive risks. A new non-hormonal IUD competitor is challenging Paragard. Furthermore, weakness in China is offsetting progress in Japan for the vision business, and the cost of the expanded sales force could hurt profit margins before it brings in new revenue.
Repeat lenses and clinic tools
Cooper makes money by selling medical products to eye doctors, fertility clinics, hospitals, and women's health providers. CooperVision sells contact lenses used daily, every two weeks, or monthly. That gives the company a repeat order base instead of a one-time sale.
CooperSurgical sells more than 600 products and services in fertility and women's health. Its Fertility line supports in-vitro fertilization, which is a process where eggs are fertilized outside the body. Products include lab media, devices, egg and sperm donation services, and genetic testing.
The moat comes from product know-how, doctor relationships, and a wide product list. In contact lenses, advanced materials like silicone hydrogel matter because comfort and eye health affect repeat use. In fertility, clinics need reliable products and services across many steps of a sensitive process.
Where this can break is clear. A product recall can create lawsuits and hurt trust. A supply issue can limit lens production. A new competitor in a niche market, like non-hormonal IUDs, can quickly take away market share and pricing power.
What Cooper sells
Biofinity contact lenses
Biofinity is CooperVision's highest-grossing brand. It helps anchor the repeat-purchase contact lens business.
Toric and multifocal lenses
These lenses treat astigmatism and presbyopia, which are more complex vision needs.
MyDay and clariti 1 day
These daily lenses serve customers who want fresh lenses each day. Daily lenses can support steady repeat demand.
MiSight 1 day
MiSight is used for myopia management in children. It was the first FDA-approved lens to slow myopia progression in children.
Fertility products and services
This line supports IVF clinics with devices, media, donor services, and genetic testing.
Paragard IUD
CooperSurgical sells this non-hormonal IUD. It previously had the market to itself but now faces a newly approved competitor.
Two segments, one bigger engine
Segment mix is based on Q3 fiscal 2026 revenue. CooperVision accounted for $717 million, and CooperSurgical accounted for $349 million.
What could break the thesis
New Paragard competitor
High impact · High oddsA newly approved non-hormonal IUD competitor is entering the market. This threatens the market share of Paragard, which was previously the only non-hormonal option.
Vision care weakness in China
Medium impact · Medium oddsInternational weakness persists in China, where sales of the MiSight contact lens declined. This completely offset the growing momentum the company saw in Japan.
Sales force expansion costs
Medium impact · Medium oddsCooperVision is aggressively expanding its sales force to drive future growth. This heavy investment could pressure operating profit margins in early 2027 before the new revenue scales up.
Embryo media litigation
High impact · Medium oddsThe company previously recorded a large litigation expense tied to an embryo culture media recall. Management noted that this fertility litigation was a factor in keeping the surgical business.
In one breath
What does The Cooper Companies do?
Cooper is a medical device company with two main businesses. CooperVision sells contact lenses, and CooperSurgical sells fertility and women's health products and services.
Why is the company keeping CooperSurgical?
The board ran a strategic review but decided to keep the business. A recent litigation settlement and a new competitor in the IUD market created a valuation disconnect, making a sale unattractive.
Why did CooperVision sales stall recently?
The company proactively reduced channel inventory in the U.S. market, which weighed on reported sales even though underlying consumer demand remained healthy.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Medical Instruments & Supplies companies
Companies near The Cooper Companies, Inc. in Finn's Medical Instruments & Supplies industry ranking.
